A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Brexpiprazole (Primary) ; Antidepressants
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms PYXIS
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 28 Aug 2023 Results of pooled analysis from (NCT01360645, NCT01360632, NCT02196506, and NCT01360866) assessing effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with MDD and prediabetes published in the Journal of Clinical Psychiatry
- 19 Sep 2022 Results of post-hoc analysis (NCT01360645, NCT01360632, NCT02196506 & NCT01727726) assessing the effects of adjunctive brexpiprazole on different symptom clusters in major depressive disorder, published in the Journal of Affective Disorders.
- 05 Oct 2021 Results of pooled and post hoc analysis from NCT01360645, NCT01360632, NCT02196506 assessing whether baseline level of functioning moderates the benefits of adjunctive brexpiprazole on life engagement, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology